Commencez à lire Cannabis: From Pariah to Prescription sur votre Kindle dans moins d'une minute. Vous n'avez pas encore de Kindle ? Achetez-le ici Ou commencez à lire dès maintenant avec l'une de nos applications de lecture Kindle gratuites.

Envoyer sur votre Kindle ou un autre appareil

 
 
 

Essai gratuit

Découvrez gratuitement un extrait de ce titre

Envoyer sur votre Kindle ou un autre appareil

Désolé, cet article n'est pas disponible en
Image non disponible pour la
couleur :
Image non disponible
 

Cannabis: From Pariah to Prescription [Format Kindle]

Ethan B Russo
4.0 étoiles sur 5  Voir tous les commentaires (1 commentaire client)

Prix conseillé : EUR 59,25 De quoi s'agit-il ?
Prix éditeur - format imprimé : EUR 53,61
Prix Kindle : EUR 37,74 TTC & envoi gratuit via réseau sans fil par Amazon Whispernet
Économisez : EUR 15,87 (30%)

App de lecture Kindle gratuite Tout le monde peut lire les livres Kindle, même sans un appareil Kindle, grâce à l'appli Kindle GRATUITE pour les smartphones, les tablettes et les ordinateurs.

Pour obtenir l'appli gratuite, saisissez votre adresse e-mail ou numéro de téléphone mobile.

Formats

Prix Amazon Neuf à partir de Occasion à partir de
Format Kindle EUR 37,74  
Relié --  
Broché EUR 53,92  




Descriptions du produit

Présentation de l'éditeur

Learn more about tomorrow’s alternative to today’s risk-laden prescription drugs!

Cannabis: From Pariah to Prescription reviews the latest research from recent clinical trials with cannabis and cannabinoids—outlining their place and future as prescription medicines. This book addresses the “road back” for cannabis medicines and society’s reacceptance of cannabis as a prescription product. This book offers physicians, patients, scientists, and students a primer on this developing branch of pharmacology and therapeutics and is ideal for use in courses for medicine, psychopharmacology, alternative medicine, health policy, and pharmacology.

Cannabis: From Pariah to Prescription assesses the genetics, horticulture, and biochemical processing of cannabis into cannabis-based medicine extracts (CBMEs). The book describes the important advanced technologies used to cultivate the genetically selected medical-grade cannabis cloned strains in glass houses. This book also discusses new advancements in drug delivery alternatives to traditional smoking, including the Advanced Delivery System (ADS)—a device that allows delivery of premeasured dosages while remaining secure, tamper-proof, and patient specific.

In Cannabis: From Pariah to Prescription, the practical applications of cannabis pharmaceuticals are explored through a wide range of clinical studies, including:
  • a thorough discussion of the latest in documented benefits and side effects when using cannabis, cannabinoids, or CBMEs
  • a tolerability study via multiple administration routes to compare pharmacodynamic effects and pharmacokinetic characteristics
  • a comparative study of the pharmacokinetic profiles administered in various areas of the buccal mucosa as well as an investigation of the pharmacokinetics of CBME administered orally
  • a blind study assessing pharmacokinetic profile of CBME administered sublingually in various ratios of cannabinoids
  • a review of several other recent trials involving CBME, THC, or cannabis
  • a study reviewing the human clinical experience to date employing synthetic cannabinoids or CBME, suggesting future treatment in the areas of obstetrics, gynecology, and pediatrics
Cannabis: From Pariah to Prescription provides extensive bibliographies to encourage your examination of previous studies and international literature. Europe remains on the cutting edge of new studies and research on cannabinoids, and much of the data in this book was collected in the United Kingdom. This meticulous resource also contains a list of abbreviations and definitions of terms from GW Pharmaceuticals to make the reading more accessible to a wide variety of readers.

Détails sur le produit

  • Format : Format Kindle
  • Taille du fichier : 6105 KB
  • Nombre de pages de l'édition imprimée : 196 pages
  • Utilisation simultanée de l'appareil : Jusqu'à  appareils simultanés, selon les limites de l'éditeur
  • Editeur : Routledge; Édition : 1 (11 juin 2014)
  • Vendu par : Amazon Media EU S.à r.l.
  • Langue : Anglais
  • ASIN: B00KX5IQEE
  • Synthèse vocale : Activée
  • X-Ray :
  • Word Wise: Non activé
  • Moyenne des commentaires client : 4.0 étoiles sur 5  Voir tous les commentaires (1 commentaire client)
  •  Souhaitez-vous faire modifier les images ?


Commentaires en ligne

5 étoiles
0
3 étoiles
0
2 étoiles
0
1 étoiles
0
4.0 étoiles sur 5
4.0 étoiles sur 5
Commentaires client les plus utiles
Par michael
Format:Broché
This book is a reprint of Journal of Cannabis Therapeutics, Volume 3, Numbers 3 and 4( 2003).

It is mostly aimed at making widely available the results of the careful clinical trials of cannabinoid sprays (ie, solutions for spraying in the nose or mouth, not smoke or tablets) in humans done by GW Pharmaceuticals in the UK as a necessary preliminary to putting their groundbreaking products on the market. Russos two excellent articles at the beginning and end provide a contrast to the three very dry but necessary and precise clinical articles.

It is certain that there must be many health and disease states (ie, inherited neurological or behavioral syndromes) associated with the endogenous cannabinoids, but the totally irrational and scientifically illiterate forces in control of western countries for the last 50 years have blocked research on all psychedelic compounds, as well us the many other important uses of the hemp plant (rope, clothing, paper, food, oil, building materials, soaps, etc) while permitting the massive socially and environmentally damaging use of tobacco, alcohol and caffeine products to flourish (perhaps mainly because it is the wealthy who control these hugely profitable addictions).

Russo and GW are the first to do controlled clinical experiments on solutions of cannabidiol and THC (the two most abundant Cannabis active agents) together. As I first pointed out in my own book on marijuana chemistry 30 years ago (now out of print but available on p2p), this is critical since CBD is always present in natural marijuana and it modulates the effects of THC. Other researchers have never used them separately or together in a spray form.
Lire la suite ›
Avez-vous trouvé ce commentaire utile ?
Commentaires client les plus utiles sur Amazon.com (beta)
Amazon.com: 4.0 étoiles sur 5  1 commentaire
4 internautes sur 4 ont trouvé ce commentaire utile 
4.0 étoiles sur 5 First reports on groundbreaking cannabis therapeutics 3 mai 2005
Par rhynchosaur - Publié sur Amazon.com
Format:Relié
This book is a reprint of Journal of Cannabis Therapeutics, Volume 3, Numbers 3 and 4 2003.

It is mostly aimed at making widely available the results of the careful clinical trials of cannabinoid sprays(ie, solutions for spraying in the nose or mouth, not smoke or tablets) in humans done by GW Pharmaceuticals in the UK as a necessary preliminary to putting their groundbreaking products on the market. Russos three excellent articles at the beginning and end provide a contrast to the three very dry but necessary and precise clinical articles.

It is certain that there must be many disease states associated with the endogenous cannabinoids. Russo and GW are the first to to controlled clinical experiments on solutions of cannabidiol and THC together. As I pointed out in my own book on marijuana chemistry 30 years ago, this is critical as CBD is always present in natural marijuana and it modulates the effects of THC. Other researchers have never used them separate or together in a spray form. This is critical as both smoke and pill forms are nearly impossible to control and titrate and this has been a major barrier to medical use. In this way , GW Pharmaceuticals hopes to make a major impact on the medical use of cannabinoids and have entered them into the drug licensing process in many countries as treatments for multiple sclerosis and other problems.

An enormous amount of research is in process on synthetic, marijuana derived and endogenous cannabinoids. This is primarily due to the discovery of the endogenous anandamides and their receptors. There are thousands of compounds that can stimulate and inhibit the activity of CB1 and CB2 receptors and the list of potential therapeutic actions is nearly coextensive with human physiology, behavior and disease. GW has greatly stimulated this field by developing advanced oral applicators which can carefully monitor the dosing and even send the data wirelessly to a central data collection point in a hospital or over the net.

Because of their wide range of actions and extremely low toxicity, it is likely that there will be numerous applications for cannabinoids including many in pediatrics and pregnancy. Of course all this is arriving to the great chagrin of the US and other governments who have long insisted that the cannabinoids were dangerous drugs with no medical use. Many have pointed out that the evidence was quite the contrary and the next few decades will provide ample proof as they enter the mainstream of medicine.
Ce commentaire a-t-il été utile ?   Dites-le-nous
Rechercher des commentaires
Rechercher uniquement parmi les commentaires portant sur ce produit

Discussions entre clients

Le forum concernant ce produit
Discussion Réponses Message le plus récent
Pas de discussions pour l'instant

Posez des questions, partagez votre opinion, gagnez en compréhension
Démarrer une nouvelle discussion
Thème:
Première publication:
Aller s'identifier
 

Rechercher parmi les discussions des clients
Rechercher dans toutes les discussions Amazon
   


Rechercher des articles similaires par rubrique